Power systems today operate in an environment where reliability and safety must be maintained despite rising loads, expanding ...

A research team led by The Hong Kong University of Science and Technology (HKUST) scholars has discovered a significant slowdown in Arctic sea ice melting since 2012, with a decrease rate of 11.3% per ...

Oncolytics has also secured FDA alignment on its pivotal Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning the company to launch the only immunotherapy ...

Targeted enrollment of 435 patients to enable potential full approval filing has been completed in OptimUM-02 trial Topline data, including median PFS, are expected in 1Q 2026 to support a potential ...

BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Carrick Therapeutics Inc., an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced positive ...

The MarketWatch News Department was not involved in the creation of this content. Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene ...

At the San Antonio Breast Cancer Symposium (SABCS), investigators reported final phase I results of an alpha-lactalbumin (aLA) vaccine designed to help prevent triple-negative breast cancer (TNBC), ...

Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus ...

A Canadian who has worked in the gaming industry for over two decades, Beck grew up on games such as Final Fantasy and Super Mario Bros. He specalizes in roleplaying games, but covers titles in almost ...

Trodelvy reduced risk of disease progression or death versus chemotherapy in patients with previously untreated metastatic triple-negative breast cancer. Treatment with Trodelvy (Sacituzumab govitecan ...